Rigel Pharmaceuticals (RIGL) reported $294M in revenue for fiscal 2025, +64.1% year on year. That ranks #2489 by revenue among 2853 SEC filers and #251 in Healthcare. Net income was $367M, a net margin of 124.7%. Revenue has grown 34.5% a year on average since 2016 ($20.4M then). The fiscal 2025 balance sheet shows $514M in total assets, $40.6M in cash and $52.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $294M | +64.1% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $125M | +418.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $367M | +1,999.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $75.7M | +140.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $450,000 | −28.2% | FY20222022-12-31 |
| Total assetsAssets | $514M | +213.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $391M | +11,806.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $40.6M | −28.5% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $52.5M | −12.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $58.8M | $8.7M | Open → |
| Q2 20262026-06-30 | $78.7M | $17.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Rigel Pharmaceuticals Inc
- Ticker
- RIGL
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001034842
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KMar 3, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Skinhealth SystemsSKIN | $301M | −$9.5M |
| EvolusEOLS | $297M | −$51.6M |
| Ironwood PharmaceuticalsIRWD | $296M | $24.0M |
| Rigel PharmaceuticalsRIGL | $294M | $367M |
| Xeris BiopharmaXERS | $292M | $554,000 |
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Rigel Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/rigel-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Rigel Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/rigel-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-rigel-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Rigel Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/rigel-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001034842-26-000015 · March 3, 2026
{{cite web |title=Rigel Pharmaceuticals — Key figures — 10-K (0001034842-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/rigl-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.